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Previously we showed that recombinant adenoviral helper-dependent (HD) vectors result in long-term
transgene expression levels in vivo which slowly declined by 95% over a period of 1 year. In this study, we
further establish that this was not predominantly immune mediated. To determine if cell turnover was
responsible for the loss of transgene expression, we induced rapid hepatocyte cell cycling in mouse liver, by
performing a surgical two-thirds partial hepatectomy. We observed a 55 and 65% reduction in transgene
expression levels and a 50 and 71% loss of vector genomes for the HD vector and the ﬁrst-generation adenoviral
vector. In sharp contrast, in nonviral, episomal plasmid DNA-injected mice, transgene expression levels and
DNA copy numbers decreased by 95 and 99%, respectively. These ﬁndings suggest that cell division alone was
not the primary reason for the slow decrease in transgene expression levels and that recombinant adenoviral
vectors have a more robust mechanism for maintaining persistence during cell cycling. Several potential
mechanisms are proposed.
Helper-dependent (HD) adenoviral vectors were demon-
strated to result in long-term expression levels of therapeutic
genes in vivo (7, 15, 23, 24, 30, 32). The in vivo performance of
adenoviral vectors was shown to be dependent on the DNA
sequences placed in the adenoviral vector (14, 29), the trans-
gene expression cassette (10, 14, 34), the mouse strain (3, 20,
33), the immediate early inﬂammatory response, and cell-me-
diated and humoral immune responses (7, 18, 32, 38). The
persistence of adenoviral vector genomes and transgene ex-
pression levels still remains a major obstacle for ﬁrst-genera-
tion (fg), multidefective, and HD vectors. Little is known about
the mechanism which is responsible for the maintenance of the
vector DNA. We recently showed, for both HD gene deletion
adenoviral vectors and fg vectors delivered into the livers of
mice, a concordant 95% falloff in transgene expression and
vector genome copy number over a period of a year (7). The
absence of a detectable humoral immune response against the
transgene product and similar ﬁndings with immunodeﬁcient
mice strongly suggest that an immune response was not re-
sponsible for the falloff in gene expression. This phenomenon
does not appear to be unique to rodents, since Morral et al.
(23) showed a 92% decline in gene expression in nonhuman
primates infused with an HD adenoviral vector over a period
of 2 years. The progressive deletion of the adenoviral genome
does not seem to be strongly inﬂuenced by the antiviral im-
mune response, because it occurs in both immunocompro-
mised (4, 20, 33) and immunocompetent (13) mice for ﬁrst-
generation, multidefective, and helper-dependent adenoviral
vectors. This is further supported by the study of Wadsworth et
al. (36), who boosted the antiadenoviral CTL response in liver-
transduced mice and found no enhanced loss in transgene
expression.
To further establish that the loss of gene expression in fg and
gene deletion adenoviral vector-treated mice was not the result
of an antigen-speciﬁc immune response directed against the
transduced cells or transgene product, C57BL/6 mice and
C57BL/6-SCID mice (Jackson Laboratory) (n  5 per group)
were injected with 8  10
8 transducing units of the HD vector
AdFTC/hFIX (Fig. 1A, I). The production of the HD vector
AdFTC/hFIX was performed as previously described (7, 11).
The ﬁnal adenoviral vector preparations were diluted in phos-
phate-buffered saline (PBS), and a total volume of 200 l was
injected into the tail vein. We found that the time courses of
transgene expression were similar for C57BL/6 and C57BL/6-
SCID mice (Fig. 1B). The highest hFIX expression levels were
observed at 2 weeks postinjection (up to 80,000 ng/ml). The
expression levels remained stable for the next months, fol-
lowed by a slow decline in hFIX concentrations in serum for
both C57BL/6 and C57BL/6-SCID mice. Taken together, these
ﬁndings further support that a cell-mediated immune response
is not the major factor responsible for the slow decline in hFIX
expression levels and the drop of genome copy numbers over
time. The progressive clearance mechanism of adenoviral vec-
tor genomes may be independent of B cells, T cells, and NK
cells and suggests that other factors might inﬂuence genome
persistence.
To further analyze the mechanism involved in adenoviral
genome persistence, we evaluated the loss of vector in the liver
of mice during cell cycling to determine if hepatocyte turnover
was responsible for the slow decline in transgene expression
levels and loss of vector genomes in vivo. Cell cycling of hepa-
tocytes was induced by performing a surgical two-thirds partial
hepatectomy after vector delivery as previously described (28).
The principle of the experiment is that after hepatectomy,
almost every hepatocyte will undergo one or two cell doublings
until the original liver mass is reconstituted. During cell cy-
cling, episomal vectors that are not directly attached to the
chromosomal DNA or contain separate centromeres/telo-
meres will not be maintained during cell division. This is con-
* Corresponding author. Mailing address: Departments of Pediat-
rics and Genetics, Room G305, School of Medicine, Stanford Univer-
sity, 300 Pasteur Dr., Stanford, CA 94305. Phone: (650) 498-6531. Fax:
(650) 498-6540. E-mail: markay@stanford.edu.
7689sistent with our previously established studies that demon-
strated a 95% reduction in episomal plasmid or recombinant
adeno-associated virus (AAV)-mediated transgene expression
and vector DNA, while integrating vectors maintained gene
expression during and after liver regeneration (6, 22, 25). It is
important to note that because we removed approximately
two-thirds of the liver, at a minimum, 66% of the vector DNA
would be removed at the time of surgery.
We compared the persistence of the HD vector genome
AdFTC/hFIX (n  8) (Fig. 1A, I) with the nonviral plasmid
vector pHM5/hFIXmg (8) (n  8) (Fig. 1A, IV). To deliver
nonviral DNA into mouse liver, a high-pressure tail vein injec-
tion was performed as previously described (19, 37). Brieﬂy, 20
g of the respective DNA diluted in 2 ml of phosphate-buff-
ered saline was injected into the tail vein of C57BL/6 mice in
5 to 7 s. Two weeks after hepatic infusion of 10
9 transducing
units of the HD adenoviral vector AdFTC/hFIX or 20 go f
the circular plasmid pHM5/hFIXmg in mice, a surgical two-
thirds partial hepatectomy was performed. Before partial hep-
atectomy, hFIX levels in serum from the HD vector AdFTC/
hFIX and pHM5/hFIXmg were stable at about 40,000 and
2,000 ng/ml, respectively (Fig. 2A). Three weeks post-partial
hepatectomy, hFIX expression levels dropped by about 56%
(18,000 ng/ml) for HD vector AdFTC/hFIX-treated animals
and 96% (80 ng/ml) for circular plasmid pHM5/hFIXmg-
treated animals (Fig. 2A). Mice injected with either AdFTC/
hFIX or pHM5/hFIXmg that did not receive a surgical two-
thirds partial hepatectomy maintained stable hFIX expression
throughout the experiment.
To establish if the posthepatectomy decline in gene expres-
sion was due to a loss of vector genomes, we determined the
relative amount of recombinant vector DNA pre- and post-
partial hepatectomy by performing Southern blot analyses
(Fig. 2B). Liver genomic DNA was extracted as previously
described (17). Twenty micrograms of genomic liver DNA pre-
and post-partial hepatectomy was digested with HindIII a re-
FIG. 1. DNA sequences used for vector production and in vivo performance of HD vectors in immunodeﬁcient mice. (A) Recombinant
adenoviral and nonviral vector genomes used in this study. All vector genomes contained the identical hFIX expression cassette in which the hFIX
minigene including a portion of the ﬁrst hFIX gene intron and the 3 untranslated region (3UTR) was driven by the human alpha-1-antitrypsin
promoter (hAAT), the liver-speciﬁc hepatocyte control region (HCR), and the apolipoprotein enhancer (ApoE). (I) DNA sequences used for
production of the HD vector AdFTC/hFIX. A 16.2-kb of alphoid repeat DNA fragment from human chromosome 17 was ﬂanked by a 4.2-kb
fragment containing the left terminus of adenovirus type 5 (nt 1 to 452), two copies of the immunoglobulin MAR (IgMAR) and by a 7.2-kb
fragment containing the hepatocyte control region, a multiple cloning site, the hFIX expression cassette, and the right terminus of adenovirus type
5 (nt 35796 to 35935). (II) The ﬁrst-generation adenoviral vector fgAd/hFIX contained the hFIX expression cassette and was deleted for the
adenoviral early genes E1 and E3. (III) Linear DNA construct L-ITR/hFIXmg, in which the hFIX expression cassette was ﬂanked by the adenoviral
5 and 3 ITR. For high-pressure tail vein injection of a linear DNA fragment in which the hFIX expression cassette was ﬂanked by the adenoviral
ITRs, the plasmid pL-ITR/hFIXmg was digested with PacI, which cuts twice, to release the plasmid backbone. (IV) Circular DNA construct
pHM5/hFIXmg, in which our most robust hFIX expression cassette was placed in the plasmid pHM5. (B) The duration of transgene expression
levels from an HD adenoviral vector shows the same time courses in C57/BL/6 and C57BL/6-SCID mice. For comparison, 8  10
9 transducing units
of the HD vector AdFTC/hFIX (see Fig. 2A) were injected via the tail vein into C57/BL/6 (F) and C57BL/6-SCID () mice. Serum samples were
collected by retro-orbital bleeding, and hFIX concentrations in serum were monitored weekly by enzyme-linked immunosorbent assay as described
earlier (7).
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input DNA. The genomic liver DNA was separated by gel
electrophoresis, transferred to a nitrocellulose membrane, and
hybridized with a [-
32]dCTP-labeled cDNA hFIX probe
(1.6-kb HindIII/EcoRI fragment from pAAVCM2), using a
random priming kit (Stratagene). We found that the adenovi-
ral vector genomes remain more stable than a circular plasmid
DNA (nonviral) vector. Three weeks post-partial hepatectomy,
the amount of nonviral vector DNA and adenoviral vector
DNA dropped by approximately 94 and 49%, respectively (Fig.
2C). The loss of vector DNA was concordant with the falloff in
transgene expression. Taken together, our results presented in
this study are in contrast to the common understanding of
episomal adenoviral vector genomes because this data and
previous studies all suggest that the genomes are slowly lost
over time. While adenovirus-mediated gene expression and
genomes slowly declined by about 95% over a period of a year,
AAV-mediated hepatic gene expression and vector genomes
do not extensively decline, even though most of the vector
genomes remain episomal (25). Taken together, recombinant
adenoviral vectors are not lost during hepatocyte cell division,
suggesting that they become uniquely associated with chromo-
somal DNA during the cell cycle.
To address whether the persistence of adenoviral vector
genomes was similar for other types of adenoviral vectors
and/or if the linear terminal ends of the adenoviral DNA alone
were sufﬁcient for persistence, we performed a further study
which compared the HD vector, AdFTC/hFIX, the ﬁrst-gen-
eration adenoviral vector fgAd/hFIX (Fig. 1A, II), and a linear
nonviral DNA fragment with the identical expression cassette
ﬂanked by the adenoviral inverted terminal repeats (ITR) (L-
ITR/hFIXmg) (Fig. 1A, III). To generate L-ITR/hFIXmg, the
vector pBITRpTP (unpublished data) was digested with ClaI
and a SpeI linker was added. The hFIX expression cassette
from pBS-ApoEHCR-hAATp-FIX-Int-3UTR-pA (21) was li-
gated into the SpeI site of pITRSpeI, resulting in pL-ITR/
hFIXmg. We infused 8  10
8 transducing particles of the
adenoviral vector fgAdFTC/hFIX (n  8) or AdFTC/hFIX (n
FIG. 2. The gutless adenoviral vector AdFTC/hFIX results in persistent transgene expression levels during the cell cycle in vivo. (A) Com-
parison of hFIX expression levels derived from episomal circular nonviral DNA and gutless adenoviral vector genomes. transducing units (10
9)o f
gutless adenoviral vector AdFTC/hFIX (F, E) and 20 g of the nonviral vector pHM5/hFIXmg ( , ) were transduced into mouse liver. To induce
the liver cell cycle, 2 weeks postinjection a surgical two-thirds partial hepatectomy was performed [F,  ]. The hFIX expression levels were
monitored before and up to 3 weeks post-partial hepatectomy by serum hFIX ELISA. Means  standard deviation are shown. (B) Southern blot
analyses and quantiﬁcation of adenoviral (I) and nonviral (II) vector DNA in mouse liver. (C) The relative loss of vector genomes before and after
partial hepatectomy was determined by phosphoimager analyses.
VOL. 77, 2003 NOTES 7691 8) or 20 g of L-ITR/hFIXmg into the livers of C57B/6 mice.
Two weeks postinjection, after the transgene expression levels
were stabilized, a two-thirds partial hepatectomy was per-
formed. We found that the transgene expression levels for both
the gene deleted and the fg adenoviral vector were equally
persistent. One day pre-partial hepatectomy, the serum hFIX
concentrations were 40,000 ng/ml for AdFTC/hFIX and 3,700
ng/ml for fgAd/hFIX, and 4 weeks post-partial hepatectomy,
the serum hFIX concentrations dropped to 18,000 and 1,300
ng/ml, respectively (Fig. 3A). This was in sharp contrast to the
FIG. 3. Relative transgene expression levels in partially hepatectomized mice after delivery of AdFTC/hFIX, fgAd/hFIX, and L-ITR/hFIXmg
into mouse liver. Transducing units (8  10
8) of AdFTC/hFIX (n  8) and 10
9 transducing units of the fg adenoviral vector fgAd/hFIX (n  8)
were injected into the tail vein of 8-week-old C57BL/6 mice, and 20 g of the linear DNA construct L-ITR/hFIXmg (n  8) was injected via
high-pressure tail vein injection. Two weeks postinjection, some mice were subjected to a two-thirds surgical partial hepatectomy (E, , ‚), and
the hFIX expression levels were monitored by hFIX ELISA. The livers of control mice which did not receive a partial hepatectomy were infused
at the same time with the adenoviral vectors AdFTC/hFIX and fgAd/hFIX and linear DNA L-ITR/hFIX (F,  , Œ). (A) Comparison of the serum
hFIX concentration in all groups as determined by enzyme-linked immunosorbent assay. The relative hFIX expression levels are shown as
percentages relative to their levels at the time of partial hepatectomy. (B) The left panel demonstrates the relative hFIX expression levels for the
adenoviral vectors AdFTC/hFIX (E, F) and fgAd/hFIX (,  ), and the right panel shows the relative hFIX levels for the linear nonviral vector
L-ITR/hFIXmg (‚, Œ). (C) Relative loss of adenoviral and nonviral DNA molecules after a surgical two-thirds partial hepatectomy. The total
vector genome copy number per 10 ng of liver genomic DNA pre- and post-partial hepatectomy for the HD vector AdFTC, the fg adenoviral vector
fgAd/hFIX, and the nonviral vector L-ITR/hFIXmg was determined by a quantitative real-time PCR assay. The left panel shows the total genome
copy number per 10 ng of genomic DNA, and the right panel summarizes the relative number of vector DNA molecules pre- and post-partial
hepatectomy. The asterisk indicates that there was a signiﬁcant difference in the drop of hFIX expression levels or genome copy numbers compared
to the other groups (P  0.05, ANOVA with a post-hoc Fisher’s test).
7692 NOTES J. VIROL.hFIX expression levels derived from the nonviral vector L-
ITR/hFIXmg, which dropped from 1,700 ng/ml pre-partial
hepatectomy to less than 100 ng/ml after hepatectomy. For
comparison, the relative hFIX expression levels pre- and post-
partial hepatectomy are summarized in Fig. 3B. The relative
hFIX expression dropped 55% for AdFTC/hFIX, 65% for
fgAd/hFIX (Fig. 3B, left panel), and 95% for L-ITR/hFIXmg
(Fig. 3B, right panel) (P  0.05, analysis of variance (ANOVA)
analysis with a post-hoc Fisher test). The dramatic loss of
serum hFIX concentrations after hepatic infusion of linear
nonviral DNA in mice that received a two-thirds partial hep-
atectomy was similar to what we observed in a previous study
(6). In concordance with these ﬁndings, we observed a dra-
matic clearance of the nonviral vector genomes after partial
hepatectomy, which was signiﬁcantly less for both the ﬁrst-
generation and HD adenoviral vectors (Fig. 3C, left panel).
The total vector genome copy numbers per 10 ng of liver
genomic DNA pre- and post-partial hepatectomy for the HD
vector AdFTC, the fg adenoviral vector fgAd/hFIX, and the
nonviral vector L-ITR/hFIXmg were determined by a quanti-
tative real-time PCR assay. For this purpose the SYBR Green
PCR Master Mix (catalog no. 4309155; PE Biosystems) in
combination with the GeneAmp5700 sequence detection sys-
tem was used. The PCR product was located in the hFIX
cDNA [nucleotides (nt) 5,032 to 5,800 from pBS-ApoEHCR(s)-
hAATp-hFIXmg-bpA], and for the ampliﬁcation, a hFIX for-
ward primer (5AAGATGCCAAACCAGGTCAATT3) and
a hFIX reverse primer (5GATAGAGCCTCCACAGAATGC
A3) were used. The results are summarized in Fig. 3C (right
panel) and expressed as the relative genome copy number.
There was a 50 and 71% decline for adenoviral vector AdFTC/
hFIX-treated animals and fgAd/hFIX-treated animals, respec-
tively, and in concordance with the hFIX expression levels, we
observed a 91% loss of nonviral vector genomes (P  0.05,
ANOVA analysis with a post-hoc Fisher test). For the control
mice that were not subjected to a surgical two-thirds partial
hepatectomy, stable hFIX concentrations in serum over the
duration of the experiment were obtained (Fig. 3A). In sum-
mary, this study implicates that episomal adenoviral vector
genomes have a more robust nuclear retention and that most
of the vector DNA remaining in the liver after partial hepa-
tectomy, unlike that observed with AAV or naked plasmid
DNA, remained in mouse liver after regeneration. Several
factors which inﬂuence genome stability may be responsible for
adenoviral vector persistence during hepatocyte turnover. As
schematically shown in Fig. 4, we present possible models that
would mechanistically explain these results. The models in-
clude vector DNA which (i) has centromeric functions (Fig.
4A), (ii), contains nuclear retention signals (Fig. 4B), (iii) rep-
licates as an episome (Fig. 4C), or (iv) integrates into the host
genome (Fig. 4D) during the cell cycle.
In a previous study we found that for fg adenoviral vectors
with a deletion of E1, adenoviral genome replication was not
the major factor responsible for vector stability in quiescent
cells in vitro and in vivo (26). We believe that these ﬁndings
make replication of adenoviral vector genomes as a potential
mechanism for persistence during cell cycling highly unlikely.
Various studies demonstrated that the integration efﬁciency of
adenoviral vector genomes occurs only at a very low efﬁciency
(12). All of the evidence together implies that centromeric
functions and/or nuclear retention signals in the adenoviral
vector genome and not episomal replication or integration are
responsible for vector persistence of adenoviral DNA mole-
cules during cell cycle in vivo. Many eukaryotic viruses are
maintained as extrachromosomal DNA molecules. There is
strong evidence that, e.g., Epstein-Barr virus and bovine pap-
illomavirus are attached to the chromosome (5, 35) to ensure
proper segregation of the viral DNA and nuclear retention
during cell division. A similar mechanism might be responsible
for persistence of adenoviral vector genomes during the cell
cycle in mouse hepatocytes.
Since the fg adenoviral vector and the HD vector share
similar features during induced cell cycle in vivo, it will be of
great interest to analyze which elements in the two vectors
have similar functions with regard to maintenance of vector
genomes during cell division. For example, it was demon-
strated that elements in the fg adenoviral vector might function
as matrix attachment regions (31), which would be one com-
mon element which exists in both the fg and the HD vector.
The HD adenoviral vector genome used in this study contains
immunoglobulin MAR (27) as a matrix attachment region
and a centromeric region of alphoid repeat DNA from human
chromosome 17 (16) as an origin of replication. It was shown
that if a mammalian origin of replication and matrix attach-
ment regions are placed in a single nonviral vector, this com-
FIG. 4. Potential mechanisms which may cause episomal persis-
tence of adenoviral vector genomes during cell cycling in vivo are
shown schematically. Four different mechanisms are proposed.
(A) The adenoviral vector genome functions as a centromere. During
cell division the spindle apparatus binds to the adenoviral vector ge-
nome, and it will be maintained in one of the daughter cells. (B) The
adenoviral vector genome has a stronger nuclear retention mechanism
than nonviral DNA. Adenoviral DNA molecules are tightly attached to
the host DNA chromatin via the adenoviral terminal protein; thus,
they will be maintained during cell division. (C) The episomal adeno-
viral genome replicates. (D) Integration of the adenoviral genome into
the host genome occurs during the cell cycle in vivo.
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cell division in vitro (2). Another similarity between fg and HD
vectors is that TP is covalently bound to the ITRs, which was
shown to stabilize the adenoviral vector genome. TP is the
proteolytical cleavage product of its precursor preterminal pro-
tein (pTP). It is known that pTP is involved in adenoviral
vector replication by forming a heterodimer with the viral
DNA polymerase, and there is strong evidence that the adeno-
viral vector genome is associated via pTP with the nuclear
matrix, generating a replication complex (1, 9, 31). Moreover,
it was demonstrated that pTP prolongs vector persistence in
vivo (17). A valid model must take into account the more rapid
rate of vector loss using adenovirus-based vectors than with
other episomal vectors, such as some plasmid vectors and
AAV, during the normal aging process, versus the more rapid
loss of nonadenoviral episomal genomes during acute and ro-
bust hepatocellular regeneration. The terminal protein com-
plexes may be directly bound the host DNA chromatin, as
indicated in Fig. 4B, or indirectly via the nuclear matrix (1, 9,
31), allowing the vector genomes to be retained during regen-
eration, but the protein may have a ﬁnite half-life in vivo that
over time, when lost, destabilizes the adenoviral genome, re-
sulting in a slow decline in vector genomes over time. At this
time we favor such a mechanism, but further studies will be
required to deﬁnitively establish this model. New insights into
the persistence of episomal vector DNA may be useful for the
development of improved episomal nonviral vectors. Taken
together, this work provides new insight into adenoviral biol-
ogy as an episomal system and shows that HD adenoviral
vectors are a powerful tool for gene therapy approaches.
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